Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06044857 · ClinicalTrials.gov registry record · Phase 1
PSMA PET Response Guided SabR in High Risk Pca
A Phase 1 study of Prostate Adenocarcinoma, sponsored by University of Texas Southwestern Medical Center.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 20
- Enrollment target
- 2
- Study locations
NCT06044857 is a Phase 1 study of Prostate Adenocarcinoma that is actively recruiting participants, run by University of Texas Southwestern Medical Center. The registered enrollment target is 20 participants, below the 218-participant average among 99 other Prostate Adenocarcinoma trials with a reported enrollment target (91% lower). The trial reports 2 study locations across 1 state.
The verdict
NCT06044857, a Phase 1 study of Prostate Adenocarcinoma, is actively recruiting participants, sponsored by University of Texas Southwestern Medical Center.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 20 participants
- Enrollment target
- 2
- Study locations
Study Summary
Sequential cohort evaluation of ideal timing of imaging and treatment spacing to discern maximal PSMA (Prostate specific membrane antigen) PET (Positron Emission Tomography) response (PSMA-11 68Ga, Illucix) for adaptation of dominant intra-prostatic lesion tumor boost dose
Conditions Studied
Interventions
- DRUG 68-Ga PSMA11
Study Locations (2)
Texas
- University of Texas Southwestern Medical Center - Dallas
- UT Southwestern Medical Center - Dallas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2024-03-07 |
| Est. Completion | 2026-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06044857
The ClinicalTrials.gov registry entry for NCT06044857 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 218-participant average among 99 other Prostate Adenocarcinoma trials with a reported enrollment target (91% lower). The listed sponsor is University of Texas Southwestern Medical Center, which has 837 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Prostate Adenocarcinoma appearing as the primary indexed condition, and to 1 intervention - of which 68-Ga PSMA11 is the first listed.
NCT06044857 reports 2 study locations spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT06044857 about?
NCT06044857 is a clinical study titled "PSMA PET Response Guided SabR in High Risk Pca". Sequential cohort evaluation of ideal timing of imaging and treatment spacing to discern maximal PSMA (Prostate specific membrane antigen) PET (Positron Emission Tomography) response (PSMA-11 68Ga, Illucix) for adaptation of dominant intra-prostatic lesion tumor boost dose
What is the current status of trial NCT06044857?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2024-03-07. Estimated completion is 2026-11.
What conditions does trial NCT06044857 study?
This clinical trial studies the following conditions: Prostate Adenocarcinoma.
What interventions are being tested in trial NCT06044857?
The interventions under investigation include: 68-Ga PSMA11 (DRUG).
Who is sponsoring clinical trial NCT06044857?
This trial is sponsored by University of Texas Southwestern Medical Center, which has 837 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06044857 being conducted?
This trial has 2 study locations across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prostate Adenocarcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
RECRUITING · Phase 1
-
Hypofractionated Accelerated Pelvic Nodal Radiotherapy (GCC 2048)
RECRUITING · Phase 1
-
Enzalutamide Implants (Enolen) in Patients With Prostate Cancer
RECRUITING · Phase 1
-
A Phase I Trial of 61Cu-NODAGA-PSMA for Patients with Prostate Cancer
RECRUITING · Phase 1
-
Bicalutamide Implants (Biolen) With Radiation Therapy in Patients With Localized Prostate Cancer
ACTIVE NOT RECRUITING · Phase 1
-
Radioligand Therapy After PSMA PET Guided External Beam Radiotherapy for Treating Post-Prostatectomy Patients With Biochemically Recurrent Prostate Cancer
ACTIVE NOT RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.